Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Affiliations

• ¹ Clinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA. [email protected].
• ² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
• ³ Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Leuven, Belgium.
• ⁴ Winship Cancer Institute, Emory University, Atlanta, GA, USA.
• ⁵ University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
• ⁶ University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
• ⁷ Centre Eugène Marquis, Rennes, France.
• ⁸ Gilead Sciences Inc., Foster City, CA, USA.
• ⁹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.